Review Paper:
Diagnostic and
Prognostic Value of MicroRNA-30 Family in Breast Cancer: A Systematic Review and
Meta-Analysis
Huynh Huu Luan, Duong Thi Chung Thuy, Nguyen Tu Linh, Nguyen Thi Ngoc Thanh and
Nguyen Thi Hue
Res. J. Biotech.; Vol. 20(8); 273-288;
doi: https://doi.org/10.25303/208rjbt2730288; (2025)
Abstract
The diagnostic and prognostic role of the microRNA-30 (miR-30) family remains inconsistent
in breast cancer (BC). This meta-analysis aimed to summarize the diagnostic and
prognostic value of miR-30s in BC. A comprehensive search was performed through
PubMed, BMC, Science Direct and Google Scholar. The QUADAS-2 and NOS tools were
used to assess the quality of the included studies. The diagnostic accuracy of miR-30
family expression was measured using the pooled sensitivity, specificity, diagnostic
odds ratio and positive/negative likelihood ratios while the pooled HR of survivals
in BC patients was used to estimate the prognostic value. All statistical analyses
were performed using R 4.1.3.
Twenty-two articles were eligible for meta-analysis. MiR-30s (-a-b-c) and (b-c-e)
expression were suggested as promising BC and metastatic-BC diagnostic biomarkers
respectively with areas under the SROC curve of 0.88. Especially, miR-30b served
as a high diagnostic accuracy biomarker for early-stage BC (AUC = 0.92). Meanwhile,
low-expression of miR-30s was associated with worse survivals in BC patients, with
HRs for OS of 0.66 [0.51–0.85], DFS of 0.72 [0.62–0.83] and PFS of 0.61 [0.52–0.72].
In BC subtypes, decreased miR-30s expression predicted reduced DFS in HER2-positive
(HR = 0.53 [0.37–0.77]) and TNBC (HR = 0.20 [0.11–0.37]), but was insignificant
on OS of TNBC (p-value = 0.095) and DFS of luminal (p-value = 0.340). miR-30s expression
was identified as BC, MBC and early-stage BC diagnostic biomarker and a valuable
prognostic biomarker for survival in patients with BC.
